Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Operating Income (2016 - 2025)

Capricor Therapeutics has reported Operating Income over the past 15 years, most recently at -$29.2 million for Q4 2025.

  • Quarterly results put Operating Income at -$29.2 million for Q4 2025, down 278.83% from a year ago — trailing twelve months through Dec 2025 was -$108.1 million (down 154.07% YoY), and the annual figure for FY2025 was -$108.1 million, down 154.07%.
  • Operating Income for Q4 2025 was -$29.2 million at Capricor Therapeutics, down from -$26.3 million in the prior quarter.
  • Over the last five years, Operating Income for CAPR hit a ceiling of -$1.3 million in Q4 2023 and a floor of -$29.2 million in Q4 2025.
  • Median Operating Income over the past 5 years was -$7.8 million (2022), compared with a mean of -$11.3 million.
  • Biggest five-year swings in Operating Income: surged 84.12% in 2023 and later tumbled 500.66% in 2024.
  • Capricor Therapeutics' Operating Income stood at -$6.4 million in 2021, then decreased by 26.44% to -$8.1 million in 2022, then surged by 84.12% to -$1.3 million in 2023, then tumbled by 500.66% to -$7.7 million in 2024, then tumbled by 278.83% to -$29.2 million in 2025.
  • The last three reported values for Operating Income were -$29.2 million (Q4 2025), -$26.3 million (Q3 2025), and -$27.7 million (Q2 2025) per Business Quant data.